StockNews.com Initiates Coverage on Cellectis (NASDAQ:CLLS)

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS - Free Report) in a research report released on Thursday morning. The firm issued a sell rating on the biotechnology company's stock.

Separately, Barclays reduced their price objective on shares of Cellectis from $7.00 to $5.00 and set an "overweight" rating for the company in a research report on Tuesday, November 5th.

Cellectis Price Performance

Shares of CLLS stock traded down $0.13 on Thursday, reaching $1.51. The company had a trading volume of 206,563 shares, compared to its average volume of 285,516. The business's 50-day moving average is $1.84 and its 200 day moving average is $2.01. The stock has a market capitalization of $83.93 million, a PE ratio of -1.16 and a beta of 3.08. Cellectis has a one year low of $1.41 and a one year high of $3.38. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48.

Cellectis (NASDAQ:CLLS - Get Free Report) last posted its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The business had revenue of $18.05 million for the quarter, compared to analyst estimates of $5.00 million. During the same quarter in the prior year, the business earned ($0.31) earnings per share. Equities research analysts forecast that Cellectis will post -0.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Cellectis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLLS. Long Focus Capital Management LLC lifted its holdings in Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company's stock worth $8,634,000 after purchasing an additional 130,000 shares in the last quarter. First Affirmative Financial Network bought a new position in shares of Cellectis in the third quarter worth approximately $45,000. Finally, XTX Topco Ltd bought a new stake in Cellectis during the second quarter valued at approximately $29,000. Institutional investors own 63.90% of the company's stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.